Table 1 Average utility values by health state for patients with wild-type KRAS tumours receiving panitumumab+BSC or BSC alone, based on the EQ-5D index

From: A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer

 

Panitumumab+BSC ( n =124)

BSC alone ( n =119)

Health state

n

Utility

n

Utility

TOX

37

0.6008

13

0.4409

TWiST

104

0.7678

103

0.6630

REL

68

0.6318

63

0.6407

  1. Abbreviations: BSC=best supportive care; EQ-5D=EuroQol-5 dimensions; REL=relapse period until death or end of follow-up; TOX=days with ⩾grade 3 adverse events; TWiST=time without symptoms or toxicity.
Back to article page